Regulatory T cells and tumour immunity - observations in mice and men

被引：83

作者：

Gallimore, Awen ^{[1
]}

Godkin, Andrew ^{[1
]}

机构：

[1] Cardiff Univ, Cardiff CF14 4XN, S Glam, Wales

来源：

IMMUNOLOGY | 2008年 / 123卷 / 02期

基金：

英国医学研究理事会;

关键词：

cancer; regulation; immune surveillance;

D O I：

10.1111/j.1365-2567.2007.02748.x

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

An enormous body of work supports a role for CD4(+) CD25(+) regulatory cells (Tregs) in shaping the immune response to tumours. Indeed, there is evidence that the cells impede effective tumour immunosurveillance, inhibit vaccine-induced antitumour immune responses and promote tumour progression. Studies exploring the impact of Tregs on tumour development are discussed in the context of manipulating this T-cell population for the purpose of cancer immunotherapy.

引用

页码：157 / 163

页数：7

共 43 条

[1] CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
Antony, PA
Piccirillo, CA
Akpinarli, A
Finkelstein, SE
Speiss, PJ
Surman, DR
Palmer, DC
Chan, CC
Klebanoff, CA
Overwijk, WW
Rosenberg, SA
Restifo, NP
[J]. JOURNAL OF IMMUNOLOGY, 2005, 174 (05) : 2591 - 2601
[2] Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma
Attia, P
Maker, AV
Haworth, LR
Rogers-Freezer, L
Rosenberg, SA
[J]. JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) : 582 - 592
[3] IMMUNOLOGICALLY MEDIATED REGRESSION OF A MURINE LYMPHOMA AFTER TREATMENT WITH ANTI-L3T4 ANTIBODY - A CONSEQUENCE OF REMOVING L3T4+ SUPPRESSOR T-CELLS FROM A HOST GENERATING PREDOMINANTLY LYT-2+ T-CELL-MEDIATED IMMUNITY
AWWAD, M
NORTH, RJ
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (06) : 2193 - 2206
[4] The impact of regulatory T cells on carcinogen-induced sarcogenesis
Betts, G.
Twohig, J.
Van den Broek, M.
Sierro, S.
Godkin, A.
Gallimore, A.
[J]. BRITISH JOURNAL OF CANCER, 2007, 96 (12) : 1849 - 1854
[5] Regulating the immune response to tumours
Betts, Gareth J.
Clarke, Sarah L.
Richards, Hannah E.
Godkin, Andrew J.
Gallimore, Awen M.
[J]. ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (08) : 948 - 961
[6] BURNET M, 1957, BRIT MED J, V5023, P841
[7] CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination
Casares, N
Arribillaga, L
Sarobe, P
Dotor, J
de Cerio, ALD
Melero, I
Prieto, J
Borrás-Cuesta, F
Lasarte, JJ
[J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (11) : 5931 - 5939
[8] Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivoi
Chen, ML
Pittet, MJ
Gorelik, L
Flavell, RA
Weissleder, R
von Boehmer, H
Khazaie, K
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (02) : 419 - 424
[9] CD4+ CD25+ FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer
Clarke, Sarah L.
Betts, Gareth J.
Plant, Andrea
Wright, Kate L.
El-Shanawany, Tariq M.
Harrop, Richard
Torkington, Jared
Rees, Brian I.
Williams, Geraint T.
Gallimore, Awen M.
Godkin, Andrew J.
[J]. PLOS ONE, 2006, 1 (02):
[10] Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, TJ
Coukos, G
Zou, LH
Alvarez, X
Cheng, P
Mottram, P
Evdemon-Hogan, M
Conejo-Garcia, JR
Zhang, L
Burow, M
Zhu, Y
Wei, S
Kryczek, I
Daniel, B
Gordon, A
Myers, L
Lackner, A
Disis, ML
Knutson, KL
Chen, LP
Zou, WP
[J]. NATURE MEDICINE, 2004, 10 (09) : 942 - 949

← 1 2 3 4 5 →